PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 3, Pages 558
Publisher
MDPI AG
Online
2021-02-02
DOI
10.3390/cancers13030558
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunotherapies in clinical development for biliary tract cancer
- (2021) Arndt Vogel et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Second-line therapies in advanced biliary tract cancers
- (2020) Sri Harsha Tella et al. LANCET ONCOLOGY
- Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma
- (2020) Bingqi Ma et al. BMC CANCER
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
- (2020) Sarina A. Piha-Paul et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
- (2020) Angela Lamarca et al. JOURNAL OF HEPATOLOGY
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
- (2020) Richard D. Kim et al. JAMA Oncology
- Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
- (2020) Changhoon Yoo et al. Journal for ImmunoTherapy of Cancer
- The Tumor Microenvironment in Cholangiocarcinoma Progression
- (2020) Luca Fabris et al. HEPATOLOGY
- Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
- (2020) Sakti Chakrabarti et al. Cancers
- Molecular profile of BRCA-mutated biliary tract cancers
- (2020) Gilbert Spizzo et al. ESMO Open
- Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers
- (2020) Wei Zhang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Impact of high tumor mutational burden in solid tumors and challenges for biomarker application
- (2020) Mairéad G. McNamara et al. CANCER TREATMENT REVIEWS
- Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
- (2020) Alessandro Rizzo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- DNA Damage and Cancer Immunotherapy: A STING in the Tale
- (2020) Timo Reisländer et al. MOLECULAR CELL
- Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
- (2020) Angela Dalia Ricci et al. Cancer Control
- Evolution of the Experimental Models of Cholangiocarcinoma
- (2020) Annamaria Massa et al. Cancers
- Is There a Role for Immunotherapy in Prostate Cancer?
- (2020) Alessandro Rizzo et al. Cells
- The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
- (2020) Angela Dalia Ricci et al. ESMO Open
- Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer
- (2020) Reham Abdel-Wahab et al. Scientific Reports
- BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care
- (2020) Alessandro Rizzo et al. Expert Review of Gastroenterology & Hepatology
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
- (2019) Zhijie Wang et al. JAMA Oncology
- Biliary tract cancers: current knowledge, clinical candidates and future challenges
- (2019) Noor-ul-Ain Tariq et al. Cancer Management and Research
- Immunotherapy in colorectal cancer: rationale, challenges and potential
- (2019) Karuna Ganesh et al. Nature Reviews Gastroenterology & Hepatology
- Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
- (2019) Tatsuya Ioka et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor mutational burden
- (2019) Lauren L. Ritterhouse CANCER CYTOPATHOLOGY
- Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications
- (2019) Hsing-Ju Wu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
- (2019) Makoto Ueno et al. Lancet Gastroenterology & Hepatology
- The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
- (2019) Thomas Powles et al. CANCER TREATMENT REVIEWS
- Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis
- (2019) Alessandro Rizzo et al. Future Oncology
- Targeting cholangiocarcinoma
- (2018) Joachim C. Mertens et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital
- (2018) Ria Winkelmann et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair
- (2018) Angela Lamarca et al. CANCER TREATMENT REVIEWS
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
- (2017) Loic Verlingue et al. EUROPEAN JOURNAL OF CANCER
- PD-L1 expression in extrahepatic cholangiocarcinoma
- (2017) Dirk Walter et al. HISTOPATHOLOGY
- Emerging molecular therapeutic targets for cholangiocarcinoma
- (2017) Sumera Rizvi et al. JOURNAL OF HEPATOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
- (2017) Katerina Ancevski Hunter et al. Molecular Diagnosis & Therapy
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
- (2017) Steven Lemery et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival and Clinical Characteristics of BRCA‐Associated Cholangiocarcinoma: A Multicenter Retrospective Study
- (2017) Talia Golan et al. ONCOLOGIST
- New Horizons for Precision Medicine in Biliary Tract Cancers
- (2017) Juan W. Valle et al. Cancer Discovery
- PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
- (2017) Jacqueline Fontugne et al. Oncotarget
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Microsatellite Instability
- (2017) Liisa Chang et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
- (2016) Faiz Gani et al. ANNALS OF SURGICAL ONCOLOGY
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
- (2016) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
- (2016) Jessica S. Brown et al. Cancer Discovery
- Tumor microenvironment: Sanctuary of the devil
- (2015) Lanlan Hui et al. CANCER LETTERS
- PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
- (2015) F. Sabbatino et al. CLINICAL CANCER RESEARCH
- Tumor Microenvironment Versus Cancer Stem Cells in Cholangiocarcinoma: Synergistic Effects?
- (2015) Maurizio Romano et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Genomic spectra of biliary tract cancer
- (2015) Hiromi Nakamura et al. NATURE GENETICS
- Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
- (2014) John Bridgewater et al. JOURNAL OF HEPATOLOGY
- Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological and molecular features
- (2014) Jau-Yu Liau et al. MODERN PATHOLOGY
- Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
- (2014) Chaitanya R. Churi et al. PLoS One
- Mutational landscape of intrahepatic cholangiocarcinoma
- (2014) Shanshan Zou et al. Nature Communications
- Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
- (2013) J. W. Valle et al. ANNALS OF ONCOLOGY
- Classification, Diagnosis, and Management of Cholangiocarcinoma
- (2012) Nataliya Razumilava et al. Clinical Gastroenterology and Hepatology
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion
- (2009) Yufu Ye et al. JOURNAL OF SURGICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More